The federal Drugs Directorate of Health Canada's Health Protection Branch has asked pharmaceutical manufacturers for a voluntary eight-month moratorium on consumer advertising of pharmaceuticals.
The agency is also proposing to hold a conference in the late spring to discuss whether the current Food and Drug Act regulations covering such advertising need to be changed.
While the Act currently prohibits any direct-to-consumer advertising of drugs other than with respect to "the brand name, proper name, common name, price and quantity of the drug," the Directorate has noted its concern at the growing amount of advertisements in consumer journals which gets around these prohibitions by providing every detail of the product except its name.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze